| CI |
Report |
Adjusted EPS |
IN-LINE |
pred ~$7.66 vs. cons $7.60 |
MEDIUM |
| CI |
Report |
Cigna Healthcare MCR |
IN-LINE |
pred ~84.7% vs. cons 84.63% |
MEDIUM |
| CI |
Report |
Specialty & Care pretax operating income |
BEAT |
pred ~$970M vs. cons $960M |
MEDIUM |
| CI |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide at least $30.35 vs. cons $30.40 |
MEDIUM |
| CI |
Guide |
FY2026 MCR |
UNCHANGED |
guide 83.7%-84.7% vs. cons 84.20% midpoint |
MEDIUM |
| CI |
Guide |
FY2026 Evernorth pretax operating income |
UNCHANGED |
guide at least $6.9B vs. cons UNVERIFIED |
LOW |
| CI |
Return |
Day-1 residual (stock − beta × S&P 500) |
-8.0% |
— |
LOW |
| CI |
Return |
5-day cumulative residual |
-7.0% (FADE) |
FADE — in-line/maintain package leaves forward estimates unchanged |
LOW |